Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
Keytruda wins second breakthrough
Merck's cancer drug Keytruda has won a second breakthrough therapy designation from the FDA.
Working Life
Gender balance in Aussie pharma still a pipedream
A recent study of the representation of women on boards and in executive positions in biotech companies in Europe and the US found women are still vastly under-represented. Are women in Australian pharmaceutical companies on the path to equal opportunity?
Approvals Action
Celgene puts up new brand of Vidaza
Celgene has registered a new brand of leukaemia treatment Vidaza while Apotex and Cipla have been active in the OTC space.
Open Forum
Not much action at CT action committee
Has the task of dealing with Australia's problems in fostering clinical trials been consigned to the bureaucratic wilderness? The latest communique from the Clinical Trials Action Group might lead one to think so.
Special Report
Aussie pharma market data: worth the price?
We asked market data users in Australian pharma for their opinions about the data they use and the providers who bring it to them and found some surprising, and some not so surprising, results.